Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy

Journal of Hypertension

Volumn 23, Issue 4, 2005, Pages 891-898

  Olsen, Michael Hecht ^a,f   Fossum, Eigil ^b   Høieggen, Aud ^b   Wachtell, Kristian ^a   Hjerkinn, Elsa ^b   Nesbitt, Shawna D ^c   Andersen, Ulrik B ^a   Phillips, Robert A ^d   Gaboury, Cynthia L ^e   Ibsen, Hans ^a   Kjeldsen, Sverre E ^b,c   Julius, Stevo ^c  

^a GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d MOUNT SINAI MEDICAL CENTER   (United States)

^e Clinical Research Group of Oregon   (United States)

^f UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Adrenergic receptor blocker; Angiotensin antagonist; Essential hypertension; Hypertrophy; Insulin resistance; Losartan; Vascular resistance

Indexed keywords

ATENOLOL; LOSARTAN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG MECHANISM; ELECTROCARDIOGRAM; FEMALE; GLUCOSE TRANSPORT; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MUSCLE BLOOD FLOW; PERIPHERAL VASCULAR DISEASE; PLETHYSMOGRAPHY; PRIORITY JOURNAL; VASCULAR RESISTANCE;

EID: 20244365050     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000163160.60234.15     Document Type: Article

References (48)

1. Kannel WB, Wilson PW, Zhang TJ. The epidemiology of impaired glucose tolerance and hypertension. Am Heart J 1991; 121:1268-1273.
2. Morris AD, Petrie JR, Connell JM. Insulin and hypertension. J Hypertens 1994; 12:633-642.
3. Laakso M, Edelman SV, Brechtel G, Baron AD. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance. J Clin Invest 1990; 85:1844-1852.
4. Yang YJ, Hope ID, Ader M, Bergman RN. Insulin transport across capillaries is rate limiting for insulin action in dogs. J Clin Invest 1989; 84:1620-1628.
5. Julius S, Gudbrandsson T, Jamerson KA, Tariq SS, Andersson O. The hemodynamic link between insulin resistance and hypertension. J Hypertens 1991; 9:983-986.
6. Jaap AJ, Hammersley MS, Shore AC, Tooke JE. Reduced microvascular hyperaemia in subjects at risk of developing type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1994; 37:214-216.
7. Serne EH, Gans RO, ter Maaten JC, Tangelder GJ, Donker AJ, Stehouwer CD. Impaired skin capillary recruitment in essential hypertension is caused by both functional and structural capillary rarefaction. Hypertension 2001; 38:238-242.
8. Antonios TF, Singer DR, Markandu ND, Mortimer PS, MacGregor GA. Structural skin capillary rarefaction in essential hypertension. Hypertension 1999; 33:998-1001.
9. Jaap AJ, Shore AC, Tooke JE. The influence of hypertension on microvascular blood flow and resistance to flow in the skin of patients with type 2 (non-insulin-dependent) diabetes. Diabet Med 1994; 11:883-887.
10. Agabiti Rosei E, Rizzoni D, Castellano M, Porteri E, Zulli R, Muiesan ML, et al. Media: lumen ratio in human small resistance arteries is related to forearm minimal vascular resistance. J Hypertens 1995; 13:341-347.
11. Greene AS, Tonellato PJ, Lui J, Lombard JH, Cowley AWJ. Microvascular rarefaction and tissue vascular resistance in hypertension. Am J Physiol 1989; 256:H126-H131.
12. Noon JP, Walker BR, Webb DJ, Shore AC, Holton DW, Edwards HV, et al. Impaired microvascular dilatation and capillary rarefaction in young adults with a predisposition to high blood pressure. J Clin Invest 1997; 99:1873-1879.
13. Struijker Boudier HA. Arteriolar and capillary remodelling in hypertension. Drugs 1999; 59:37-40.
14. Lillioja S, Young AA, Culter CL, Ivy JL, Abbott WG, Zawadzki JK, et al. Skeletal muscle capillary density and fiber type are possible determinants of in vivo insulin resistance in man. J Clin Invest 1987; 80:415-424.
15. Serne EH, Gans RO, ter Maaten JC, ter Wee PM, Donker AJ, Stehouwer CD. Capillary recruitment is impaired in essential hypertension and relates to insulin's metabolic and vascular actions. Cardiovasc Res 2001; 49:161-168.
16. Serne EH, Stehouwer CD, ter Maaten JC, ter Wee PM, Rauwerda JA, Donker AJ, et al. Microvascular function relates to insulin sensitivity and blood pressure in normal subjects. Circulation 1999; 99:896-902.
17. Possum E, Høieggen A, Moan A, Rostrup M, Nordby G, Kjeldsen SE. Relationship between insulin sensitivity and maximal forearm blood flow in young men. Hypertension 1998; 32:838-843.
18. Jamerson KA, Julius S, Gudbrandsson T, Andersson O, Brant DO. Reflex sympathetic activation induces acute insulin resistance in the human forearm. Hypertension 1993; 21:618-623.
19. Scherrer U, Randin D, Vollenweider P, Vollenweider L, Nicod P. Nitric oxide release accounts for insulin's vascular effects in humans. J Clin Invest 1994; 94:2511-2515.
20. Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation 1993; 87:1468-1474.
21. Schiffrin EL, Deng LY. Comparison of effects of angiotensin I-converting enzyme inhibition and beta-blockade for 2 years on function of small arteries from hypertensive patients. Hypertension 1995; 25:699-703.
22. Baron AD, Steinberg HO, Chaker H, Leaming R, Johnson AK, Brechtel G. Insulin-mediated skeletal muscle vasodilation contributes to both insulin sensitivity and responsiveness in lean humans. J Clin Invest 1995; 96:786-792.
23. Christensen KL, Mulvany MJ. Vasodilatation, not hypotension, improves resistance vessel design during treatment of essential hypertension: a literature survey. J Hypertens 2001; 19:1001-1006.
24. Schiffrin EL, Park JB, Intengan HD, Touyz RM. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan [see comments]. Circulation 2000; 101:1653-1659.
25. Lithell HO. Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care 1991; 14:203-209.
26. Moan A, Hoieggen A, Seljeflot I, Risanger T, Arnesen H, Kjeldsen SE. The effect of angiotensin II receptor antagonism with losartan on glucose metabolism and insulin sensitivity. J Hypertens 1996; 14:1093-1097.
27. Olsen MH, Fossum E, Hjerkinn E, Wachtell K, Høieggen A, Nesbitt SD, et al. Relative influence of insulin resistance versus blood pressure on vascular changes in longstanding hypertension. ICARUS, a LIFE substudy. J Hypertens 2000; 18:75-81.
28. Dahlof B, Devereux RB, Julius S, Kjeldsen SE, Beevers G, de Faire U, et al. Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study [In process citation]. Hypertension 1998; 32:989-997.
29. DeFronzo RA, Simonson D, Ferrannini E. Hepatic and peripheral insulin resistance: a common feature of type 2 (non-insulin-dependent) and type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1982; 23:313-319.
30. Polonsky KS, Given BD, van Cauter E. Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. J Clin Invest 1988; 81:442-448.
31. Ader M, Bergman RN. Insulin sensitivity in the intact organism. Baillieres Clin Endocrinol Metab 1987; 1:879-910.
32. Folkow B. Physiological aspects of primary hypertension. Physiol Rev 1982; 62:347-504.
33. Cooper KE, Edholm OG, Mottram RF. The blood flow in skin and muscle of the human forearm. J Physiol (Lond) 1954; 128:258-267.
34. Andersen L, Dinesen B, Jorgensen PN, Poulsen F, Roder ME. Enzyme immunoassay for intact human insulin in serum or plasma. Clin Chem 1993; 39:578-582.
35. Olsen MH, Andersen UB, Wachtell K, Ibsen H, Dige-Petersen H. A possible link between endothelial dysfunction and insulin resistance in hypertension. A LIFE substudy. Losartan Intervention For Endpoint-Reduction in Hypertension [In process citation]. Blood Press 2000; 9:132-139.
36. Irving RJ, Walker BR, Noon JP, Watt GC, Webb DJ, Shore AC. Microvascular correlates of blood pressure, plasma glucose, and insulin resistance in health. Cardiovasc Res 2002; 53:271-276.
37. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003.
38. Opie LH, Schall R. Old antihypertensives and new diabetes. J Hypertens 2004; 22:1453-1458.
39. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363:2022-2031.
40. Julius S, Weber MA. VALUE: analysis of results. Lancet 2004; 364:935.
41. Lindholm LH, Ibsen H, Borch-Johnsen K, Olsen MH, Wachtell K, Dahlof B, et al. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 2002; 20:1879-1886.
42. Reneland R, Alvarez E, Andersson PE, Haenni A, Byberg L, Lithell H. Induction of insulin resistance by beta-blockade but not ACE-inhibition: long-term treatment with atenolol or trandolapril. J Hum Hypertens 2000; 14:175-180.
43. Henriksen EJ, Jacob S, Kinnick TR, Teachey MK, Krekler M. Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats. Hypertension 2001; 38:884-890.
44. Jamerson KA, Nesbitt SD, Amerena JV, Grant E, Julius S. Angiotensin mediates forearm glucose uptake by hemodynamic rather than direct effects. Hypertension 1996; 27:854-858.
45. Herbertsson P, Fagher B. Effects of verapamil and atenolol on exercise tolerance in 5,000 m cross-country running: a double-blind crossover study in normal humans. J Cardiovasc Pharmacol 1990; 16:23-27.
46. Thompson PD, Cullinane EM, Nugent AM, Sady MA, Sady SP. Effect of atenolol or prazosin on maximal exercise performance in hypertensive joggers. Am J Med 1989; 86:104-109.
47. Lamont LS. Beta-blockers and their effects on protein metabolism and resting energy expenditure. J Cardiopulm Rehabil 1995; 15:183-185.
48. Bachman ES, Dhillon H, Zhang CY, Cinti S, Bianco AC, Kobilka BK, et al. betaAR signaling required for diet-induced thermogenesis and obesity resistance. Science 2002; 297:843-845.